BioCentury
ARTICLE | Clinical News

Niraparib: Phase III started

July 29, 2013 7:00 AM UTC

Tesaro began the double-blind, placebo-controlled, international Phase III NOVA trial to evaluate once-daily 300 mg niraparib in 28-day cycles in about 360 patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer. The trial will enroll patients into 1 of 2 independent cohorts based on germline breast cancer early onset (BRCA) mutation status. Tesaro has exclusive, worldwide rights to niraparib from Merck (see BioCentury, June 11, 2012). ...